ArticleLa Radiologia medica2026
Integrated radiomics and machine learning approach for ras mutation status prediction in colorectal liver metastases.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRAS mutational status is a critical prognostic biomarker in colorectal liver metastases (CRLM), traditionally assessed via tissue biopsy. This study evaluates the potential of radiomic features extracted from CT and MRI to non-invasively predict RAS mutations using machine learning algorithms.
methodsIn this study, 77 CRLM metastases (mean size 34.9; range 17-56 mm) with known RAS mutational status were analyzed. Radiomic features were extracted from hepatobiliary-phase MRI and portal venous-phase CT. After removing highly correlated features (Pearson |r| > 0.7) and applying z-score normalization, LASSO logistic regression with repeated tenfold cross-validation was used for feature selection. A total of 41 predictive features were identified. The dataset was split into training (70%) and testing (30%), ensuring that all lesions from a given patient were assigned exclusively to either the training or testing set. To address class imbalance in the training data, the Random Over Sampling Examples (ROSE) algorithm was applied exclusively to the training set. Six classification models (Stepwise Logistic Regression, LASSO, Random Forest, GBM, Neural Network, and CART) were trained and evaluated using ROC/AUC and other diagnostic metrics. DeLong's test was applied for pairwise AUC comparisons.
resultsMRI-derived features, particularly from wavelet-transformed gldm and first-order matrices, showed strong predictive power, with several achieving > 0.75 AUC individually. The gradient boosting machine (GBM) outperformed all other models with an AUC of 0.998 and an accuracy of 95.6%. Random forest and CART also demonstrated high discriminative performance (AUCs of 0.990 and 0.914, respectively). Nine features were consistently ranked among the top 20 predictors across all models, suggesting robust modality-independent imaging biomarkers. DeLong's test confirmed statistically significant AUC differences between GBM and logistic regression models (p < 0.05).
conclusionsThe results of this pilot study suggest that radiomic analysis combining CT and MRI modalities, particularly when processed through ensemble machine learning methods, holds the potential to accurately predict RAS mutational status in CRLM. While promising, these findings should be interpreted with caution, considering the study's limitations, including the small patient cohort and its design. These factors highlight the need for prospective validation in larger, multicenter cohorts to confirm the generalizability of the models. Nevertheless, these preliminary results support the use of multiparametric radiomics as a potential non-invasive tool for preoperative molecular stratification.
Indexed as
Identifiers
41145899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.